현재 각막 부종의 치료법에는 근본적인 원인과 중증도에 따른 전용 전략이 포함되어 있습니다. 초기 관리에는 염증을 억제하고 각막에서 과도한 액체를 제거하기 위해 식염수나 국소 스테로이드를 사용하는 경우가 많습니다. 경구 또는 외용 탄산탈수효소 억제제와 같은 고삼투압 약물도 사용됩니다. 붕대 콘택트렌즈는 각막 표면을 매끄럽게 하고 시력을 개선하여 증상을 완화시킬 수 있습니다. 각막 내피가 심하게 손상된 경우, 데스메탈박리내피각막이식술(DSEK)이나 데스메탈내피각막이식술(DMEK)과 같은 각막이식술과 같은 외과적 개입이 고려됩니다. 선택적 레이저 섬유주 절제술(SLT)과 같은 레이저 치료는 이차성 녹내장이 동반된 경우에 사용할 수 있습니다. 또한, 부종을 유발하는 기저 질환을 치료하고 윤활을 위해 인공누액을 사용하는 것도 종합적인 치료 계획의 일부가 될 수 있으며, TTHX1114나 시롤리무스와 같은 임상시험용 약물에서 볼 수 있듯이 혁신적인 치료법을 찾기 위한 지속적인 연구로 인해 각막 부종 관리의 선택지는 앞으로 더욱 확대될 수 있습니다.
각막 부종 시장은 EO2002, TTHX1114 등과 같은 잠재적 약물의 승인으로 인해 긍정적인 성장이 예상됩니다.
이 보고서는 미국 각막 부종 시장을 조사 분석하여 각 지역별 시장 규모, 현재 치료법, 미충족 수요, 신약 등의 정보를 제공합니다.
DelveInsight's "Corneal Edema- Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the corneal edema, historical and forecasted epidemiology and the corneal edema market trends in the United States.
The Corneal Edema market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted United States Corneal Edema market size from 2020 to 2034. The report also covers current Corneal Edema treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2020-2034
Corneal Edema Overview
Corneal edema is characterized by the swelling of the cornea, the transparent, dome-shaped outer layer of the eye that shields the iris and pupil. The cornea is pivotal in directing light onto the retina to facilitate clear vision. The occurrence of corneal edema arises from an excess accumulation of fluid within the cornea, resulting in a blurred or cloudy visual appearance.
Corneal edema can manifest due to diverse factors, each contributing to the accumulation of excessive fluid within the cornea and resulting in a cloudy or hazy visual appearance. One prevalent cause is endothelial dysfunction, characterized by impairment in the cells lining the inner surface of the cornea, known as the endothelium. Conditions like Fuchs' dystrophy or damage from intraocular surgery can compromise the regulatory function of endothelial cells, leading to edema. Trauma or direct injury to the eye can also trigger corneal swelling. Inflammatory conditions, such as uveitis, exacerbate corneal edema by inducing inflammation within the eye.
Corneal edema presents with distinctive symptoms that affect both vision and overall eye comfort. A key symptom is the occurrence of blurred or hazy vision, a consequence of light scattering due to the buildup of fluid in the cornea. Individuals affected by corneal edema often encounter a significant reduction in visual acuity, leading to difficulties in perceiving fine details clearly. Another prevalent symptom is sensitivity to light, referred to as photophobia.
Corneal Edema Diagnosis
The diagnosis of corneal edema involves a comprehensive eye examination conducted by an ophthalmologist. Clinical evaluation typically includes a thorough assessment of the patient's medical history, symptoms, and any relevant contributing factors. Specialized tests, such as corneal topography or pachymetry, may be employed to measure corneal thickness and assess the extent of edema. Slit-lamp biomicroscopy allows for a detailed examination of the cornea, enabling the clinician to observe any signs of swelling, cloudiness, or changes in endothelial cell density. Additionally, visual acuity tests help quantify the impact of corneal edema on the patient's vision.
Corneal Edema Treatment
The treatment of corneal edema is tailored to address its underlying cause. In cases where endothelial dysfunction is a contributing factor, therapies may include hypertonic saline solutions to draw excess fluid from the cornea or the use of hyperosmotic agents for reducing swelling. Lubricating eye drops, often in the form of artificial tears, can provide relief from discomfort and dryness associated with corneal edema. In more severe instances, surgical interventions such as corneal transplantation may be considered to replace damaged tissue.
As the market is derived using the patient-based model, the Corneal Edema epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Etiology-specific Diagnosed Prevalent Cases of Corneal Edema, and Total Diagnosed Prevalent Cases of Corneal Edema covering the United States from 2020 to 2034.
As per DelveInsight's estimations, the total diagnosed prevalent cases of Corneal Edema in the United States were approximately 1,149,967 in 2022 and are projected to increase during the forecast period.
The drug chapter segment of the Corneal Edema report encloses a detailed analysis of corneal edema marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also understands Corneal Edema clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Emerging Drugs
EO2002: Emmetrope Ophthalmics LLC
EO2002, developed by Emmecell, is a pioneering non-surgical magnetic cell-based therapy designed to modify diseases, particularly addressing corneal edema secondary to corneal endothelial dysfunction. This innovative therapy utilizes the exclusive Magnetic Cell Delivery (MCD) nanoparticle platform, allowing for easier access to treatment before the onset of disability and pain. EO2002 has the potential to prevent or delay the need for more invasive procedures like corneal transplantation. Currently, in Phase I evaluation (EMME-01 study), it aims to assess safety and tolerability in eyes qualifying for full-thickness corneal transplantation or endothelial keratoplasty.
TTHX1114: Trefoil Therapeutics
TTHX1114 is an investigational-engineered variant of the naturally occurring molecule fibroblast growth factor-1 (FGF1), which stimulates corneal endothelial and epithelial cell proliferation and migration as well as protects these cells from stress and injury. Trefoil is conducting clinical trials for TTHX1114 as an intracameral injection in patients susceptible to corneal edema due to endothelial damage, including Fuchs endothelial corneal dystrophy (FECD) and other corneal endothelial dystrophies (CED) and patients with other risk factors undergoing ocular surgeries. The drug is aimed at protecting and regenerating corneal endothelial cells lost due to disease and thereby improving vision.
Note: Detailed emerging therapies assessment will be provided in the final report of Corneal Edema
The current treatment approach for corneal edema involves a tailored strategy based on the underlying cause and severity of the condition. Initial management often includes the use of hypertonic saline solutions and topical steroids to reduce inflammation and draw out excess fluid from the cornea. Hyperosmotic agents, such as oral or topical carbonic anhydrase inhibitors, may also be employed. Bandage contact lenses can provide relief by creating a smoother corneal surface, improving vision. In cases where the corneal endothelium is severely compromised, surgical interventions like corneal transplantation, including Descemet's Stripping Endothelial Keratoplasty (DSEK) or Descemet's Membrane Endothelial Keratoplasty (DMEK), may be considered. Laser procedures, such as Selective Laser Trabeculoplasty (SLT), could be utilized in cases associated with secondary glaucoma. Additionally, addressing the underlying conditions contributing to edema and the use of artificial tears for lubrication may be part of the comprehensive treatment plan. The approach is dynamic, with ongoing research exploring innovative therapies, as seen in investigational drugs like TTHX1114 and sirolimus, potentially expanding the options for managing corneal edema in the future.
The market for Corneal Edema is expected to experience positive growth with the approval of potential drugs like EO2002, TTHX1114 and others.
This section focuses on the uptake rate of potential drugs expected to launch in the market during 2020-2034. For example, EO2002 in the US is expected to be launched by 2028.
Further detailed analysis of emerging therapies drug uptake in the report…
Corneal Edema Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Corneal Edema emerging therapies.
KOL Views
To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on Corneal Edema evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including KOL from University of Utah Hospital, the US, Department of Ophthalmology, Columbia University, New York, US, Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, Departments of Cornea and External Diseases, Scripps Clinic Torrey Pines, La Jolla, California and others.
DelveInsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the US. Their opinion helps understand and validate current and emerging therapies, treatment patterns, or corneal edema market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
Qualitative Analysis
We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.
Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.
Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.
Market Access and Reimbursement
The high cost of therapies for the treatment is a major factor restraining the growth of the drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment.
The report further provides detailed insights on the country accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.
Market Insights
Epidemiology Insights
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies
Frequently Asked Questions